ongoing trials - trial from www.clinicaltrials.gov

Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis - Phase 2|Phase 3 - Not yet recruiting

Code: NCT05408910 **Year:** 2022 **Date:** September 2022

Author: Wake Forest University Health Sciences|Emory University|University of Minnesota|University of Texas Southwestern Medical Center

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment

Participants

Cystic Fibrosis|Abdominal Pain|Small Bowel Disease - 12 Years and older (Child, Adult, Older Adult)

Interventions

Drug: Rifaximin 550 MG Oral Tablet [XIFAXAN]|Drug: Placebo

Outcome measures

Rifaximin Treatment Group Improvement of Symptoms|Improved ePROS scores

https://ClinicalTrials.gov/show/NCT05408910

Keywords

Rifaximin; other anti-bacterial agents; Anti-Bacterial Agents; pharmacological_intervention;